Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

226
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
226
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hydroxyurea-associated digital gangrene: a case report and narrative review of reported cases and emerging pathophysiology.

Thrombosis journal·2026
Same author

A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors.

NPJ precision oncology·2026
Same author

Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial.

Nature communications·2026
Same author

Socio-behavioral determinants of early vs. long-term HIV infection in Kazakhstan: roles of self-testing, alcohol, drug use and sexual networks.

Frontiers in public health·2025
Same author

Overcoming ovarian cancer resistance and evasion to CAR-T cell therapy by harnessing allogeneic CAR-NKT cells.

Med (New York, N.Y.)·2025
Same author

Extracellular vesicle digital scoring assay for assessment of treatment responses in hepatocellular carcinoma patients.

Journal of experimental & clinical cancer research : CR·2025

Related Experiment Video

Updated: Sep 4, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K

Infigratinib for cholangiocarcinoma.

Saeed Sadeghi1

  • 1UCLA, Division of Hematology and Oncology, Los Angeles, California, USA. ssadeghi@mednet.ucla.edu.

Drugs of Today (Barcelona, Spain : 1998)
|July 19, 2022
PubMed
Summary

Infigratinib, a targeted therapy for cholangiocarcinoma (CCA), shows promise for advanced bile duct cancer. This FGFR inhibitor offers a new treatment option for patients with specific genetic alterations.

Keywords:
CholangiocarcinomaFibroblast growth factor receptor (FGFR) inhibitorsGastrointestinal cancerInfigratinibSolid tumors

More Related Videos

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.3K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

399

Related Experiment Videos

Last Updated: Sep 4, 2025

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma
07:59

Portal Vein Injection of Colorectal Cancer Organoids to Study the Liver Metastasis Stroma

Published on: September 3, 2021

6.5K
Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice
05:22

Intracranial Cannula Implantation for Serial Locoregional Chimeric Antigen Receptor CAR T Cell Infusions in Mice

Published on: February 24, 2023

3.3K
Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb
04:50

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

399

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cholangiocarcinoma (CCA) is a bile duct cancer with a poor prognosis and low survival rates.
  • Advanced or metastatic CCA presents significant treatment challenges.
  • Current standard care involves gemcitabine and cisplatin chemotherapy.

Purpose of the Study:

  • To review infigratinib, a targeted therapy for cholangiocarcinoma.
  • To discuss its mechanism of action as a fibroblast growth factor receptor (FGFR) inhibitor.
  • To highlight its FDA approval for specific patient populations.

Main Methods:

  • Review of existing clinical trial data, focusing on Phase II efficacy.
  • Analysis of infigratinib's molecular targeting of FGFR.
  • Examination of regulatory approval criteria and outcomes.

Main Results:

  • Infigratinib demonstrated positive efficacy in Phase II trials for CCA.
  • The drug is an oral small-molecule tyrosine kinase inhibitor targeting FGFR.
  • Accelerated FDA approval was granted based on these findings.

Conclusions:

  • Infigratinib represents a significant advancement in targeted therapy for CCA.
  • It offers a new treatment avenue for patients with FGFR2 fusions or rearrangements.
  • This targeted approach addresses the need for improved outcomes in advanced CCA.